Inovio Pharmaceuticals Inc. (INO) News

Inovio Pharmaceuticals Inc. (INO): $0.38

0.00 (0.08%)

POWR Rating

Component Grades

Momentum

F

Stability

F

Sentiment

Quality

C

Add INO to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#201 of 394

in industry

Filter INO News Items

INO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

INO News Highlights

  • For INO, its 30 day story count is now at 3.
  • Over the past 9 days, the trend for INO's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about INO are DNA and DRUG.

Latest INO News From Around the Web

Below are the latest news stories about INOVIO PHARMACEUTICALS INC that investors may wish to consider to help them evaluate INO as an investment opportunity.

INOVIO Announces U.S. FDA Breakthrough Therapy Designation Granted for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for INO-3107 as a potential treatment for patients with Recurrent Respiratory Papillomatosis (RRP). The FDA's Breakthrough Therapy designation is a process designed to expedite the development and

Yahoo | September 7, 2023

Philadelphia-area life sciences firms have now cut more than 500 jobs since the start of 2022

Among the dozen Philadelphia-area life sciences firms that have enacted layoffs since the start of last year, two companies have each trimmed their workforces three separate times.

Yahoo | September 7, 2023

INOVIO to Present at the H.C. Wainwright 25th Annual Global Investment Conference

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Dr. Jacqueline Shea, President and CEO will present at the H.C. Wainwright 25th Annual Global Investment Conference.

Yahoo | August 29, 2023

Inovio Pharmaceuticals (INO) Q2 2023 Earnings Call Transcript

Good afternoon, and thank you for joining the Inovio 2023 second-quarter conference call. Joining me on today's call are Dr. Jackie Shea, president and CEO; Dr. Michael Sumner, chief medical officer; and Mr.

Yahoo | August 10, 2023

Inovio Pharmaceuticals (INO) Reports Q2 Loss, Tops Revenue Estimates

Inovio (INO) delivered earnings and revenue surprises of 7.14% and 13%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 9, 2023

INOVIO Announces Second Quarter 2023 Financial Results and Provides Strategic Update

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the second quarter ended June 30, 2023 and provided a strategic update.

Yahoo | August 9, 2023

INOVIO Reports Inducement Grants Under Inducement Plan

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that it has made equity grants to two newly hired employees under its 2022 Inducement Plan (the "Inducement Plan").

Yahoo | August 4, 2023

INOVIO to Report Second Quarter 2023 Financial Results on August 9, 2023

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that second quarter 2023 financial results will be released after the market close on August 9, 2023. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update.

Yahoo | July 26, 2023

INOVIO Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

Plymouth Meeting, Pa., June 23, 2023 (GLOBE NEWSWIRE) -- INOVIO (NASDAQ:INO) has released the following pursuant to an order of the UNITED STATES DISTRICT COURT EASTERN DISTRICT OF PENNSYLVANIA: UNITED STATES DISTRICT COURT EASTERN DISTRICT OF PENNSYLVANIA IN RE INOVIO PHARMACEUTICALS, INC. DERIVATIVE LITIGATION Lead Case No. 2:20-cv-01962-GJP NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF STOCKHOLDER DERIVATIVE ACTIONS TO: ALL RECORD HOLDERS AND BENEFICIAL OWNERS OF INOVIO PHARMACEUTICALS, INC.

Yahoo | June 23, 2023

INOVIO to Present at the 2023 Jefferies Healthcare Conference

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Dr. Jacqueline Shea, President and CEO, and Dr. Michael Sumner, CMO, will present at the 2023 Jefferies Healthcare Conference.

Yahoo | May 25, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!